News
KRRO
8.81
-5.37%
-0.50
Korro Bio management to meet with Piper Sandler
TipRanks · 9h ago
Weekly Report: what happened at KRRO last week (1005-1009)?
Weekly Report · 4d ago
Korro Bio Doses First Cohort In Phase 1/2 Study Of KRRO-121 For Hyperammonemia
NASDAQ · 10/07 05:34
Oppenheimer Reaffirms Their Buy Rating on Korro Bio (KRRO)
TipRanks · 10/06 11:55
Piper Sandler Reaffirms Their Buy Rating on Korro Bio (KRRO)
TipRanks · 10/06 11:15
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO), Korro Bio (KRRO) and HeartBeam (BEAT)
TipRanks · 10/06 10:40
Buy Rating Reiterated on KRRO as Early Clinical Execution, ANCHOR Trial Design and Cash Runway Support Unchanged $21 Price Target
TipRanks · 10/06 10:35
Korro Bio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 10/06 10:26
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
Benzinga · 10/06 10:16
Korro Bio Begins First Human Trial of KRRO-121 Therapy
TipRanks · 10/05 20:29
Korro Bio doses first cohort of participants in KRRO-121 trial
TipRanks · 10/05 20:10
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Benzinga · 10/05 20:10
Weekly Report: what happened at KRRO last week (0928-1002)?
Weekly Report · 10/05 09:32
Favorable FDA Readthrough De-Risks Korro’s KRRO-111; Buy Rating Reaffirmed with Unchanged $21 Price Target
TipRanks · 10/01 16:55
Weekly Report: what happened at KRRO last week (0921-0925)?
Weekly Report · 09/28 09:31
Weekly Report: what happened at KRRO last week (0914-0918)?
Weekly Report · 09/21 09:31
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/18 17:05
Weekly Report: what happened at KRRO last week (0907-0911)?
Weekly Report · 09/14 09:32
Citi Sticks to Its Buy Rating for Korro Bio (KRRO)
TipRanks · 09/10 10:26
Weekly Report: what happened at KRRO last week (0831-0904)?
Weekly Report · 09/07 09:30
More
Webull provides a variety of real-time KRRO stock news. You can receive the latest news about Korro Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.